Risk of diabetes in children and adolescents exposed to antipsychotics: A nationwide 12-year case-control study

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 53, Issue 9, 2014, Pages

  Nielsen, René Ernst ^a   Laursen, Mathilde Frahm ^a   Lammers Vernal, Ditte ^a   Bisgaard, Charlotte ^a   Jakobsen, Helle ^a   Steinhausen, Hans Christoph ^a   Correll, Christoph U ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Antipsychotics; diabetes; risk factors

Indexed keywords

NEUROLEPTIC AGENT; ORAL ANTIDIABETIC AGENT;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; CASE CONTROL STUDY; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SEX DIFFERENCE; CHEMICALLY INDUCED; DENMARK; DIABETES MELLITUS, TYPE 2; REGISTER; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHILD; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; REGISTRIES;

EID: 84906535192     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2014.04.023     Document Type: Article

References (43)

1. M. Olfson, C. Blanco, S.M. Liu, S. Wang, and C.U. Correll National trends in the office-based treatment of children, adolescents, and adults with antipsychotics Arch Gen Psychiatry 69 2012 1247 1256
2. H.C. Steinhausen, and C. Bisgaard Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in denmark Acta Psychiatr Scand 129 2014 221 231
3. B.G. Schimmelmann, S.J. Schmidt, M. Carbon, and C.U. Correll Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach Curr Opin Psychiatry 26 2013 219 230
4. C.U. Correll, C.J. Kratochvil, and J.S. March Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics J Clin Psychiatry 72 2011 655 670
5. D. Fraguas, C.U. Correll, and J. Merchan-Naranjo et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons Eur Neuropsychopharmacol 21 2011 621 645
6. A. Zuddas, R. Zanni, and T. Usala Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies Eur Neuropsychopharmacol 21 2011 600 620
7. V. Roessner, K.J. Plessen, and A. Rothenberger et al. European clinical guidelines for tourette syndrome and other tic disorders. part II: pharmacological treatment Eur Child Adolesc Psychiatry 20 2011 173 196
8. M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje National trends in the outpatient treatment of children and adolescents with antipsychotic drugs Arch Gen Psychiatry 63 2006 679 685 (Pubitemid 43848299)
9. P. Pathak, D. West, B.C. Martin, M.E. Helm, and C. Henderson Evidence-based use of second-generation antipsychotics in a state medicaid pediatric population, 2001-2005 Psychiatr Serv 61 2010 123 129
10. C. Panagiotopoulos, R. Ronsley, B. Kuzeljevic, and J. Davidson Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics Can J Psychiatry 57 2012 34 44
11. C.U. Correll, and J.M. Kane One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review J Child Adolesc Psychopharmacol 17 2007 647 656
12. L. Maayan, and C.U. Correll Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents J Child Adolesc Psychopharmacol 21 2011 517 535
13. M. De Hert, M. Dobbelaere, E.M. Sheridan, D. Cohen, and C.U. Correll Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice Eur Psychiatry 26 2011 144 158
14. M. De Hert, J. Detraux, R. van Winkel, W. Yu, and C.U. Correll Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat Rev Endocrinol 8 2011 114 126
15. C.U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA 302 2009 1765 1773
16. V. Eapen, D. Shiers, and J. Curtis Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication Aust N Z J Psychiatry 47 2013 435 442
17. V. Eapen, and G. John Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go? Australas Psychiatry 19 2011 232 235
18. L.A. Kryzhanovskaya, W. Xu, B.A. Millen, N. Acharya, K.Y. Jen, and O. Osuntokun Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine J Child Adolesc Psychopharmacol 22 2012 157 165
19. T. Pringsheim, D. Lam, H. Ching, and S. Patten Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials Drug Saf 34 2011 651 668
20. C. Rummel-Kluge, K. Komossa, and S. Schwarz et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Schizophr Res 123 2010 225 233
21. J. Nielsen, S. Skadhede, and C.U. Correll Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients Neuropsychopharmacology 35 2010 1997 2004
22. C.U. Correll, T. Lencz, and A.K. Malhotra Antipsychotic drugs and obesity Trends Mol Med 17 2011 97 107
23. S.E. Andrade, J.C. Lo, and D. Roblin et al. Antipsychotic medication use among children and risk of diabetes mellitus Pediatrics 128 2011 1135 1141
24. World Health Organisation ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines 1992 World Health Organisation Geneva
25. T. Kishi, V. Kafantaris, S. Sunday, E.M. Sheridan, and C.U. Correll Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis J Clin Psychiatry 73 2012 e757 e766
26. O. Mors, G.P. Perto, and P.B. Mortensen The danish psychiatric central research register Scand J Public Health 39 7 Suppl 2011 54 57
27. H.W. Kildemoes, H.T. Sorensen, and J. Hallas The Danish National Prescription Registry Scand J Public Health 39 7 Suppl 2011 38 41
28. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index 2009 World Health Organization
29. D.G. Altman Confidence intervals for the number needed to treat Br Med J 317 1998 1309 1312 (Pubitemid 28502420)
30. K. Bull, and D.J. Spiegelhalter Survival analysis in observational studies Stat Med 16 1997 1041 1074
31. J.M. Jerrell, A. Tripathi, A.A. Rizvi, and R.S. McIntyre The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis Prim Care Companion CNS Disord 14 2012 pii:PCC.11m01185. doi: 10.4088/PCC.11m01185
32. C.H. Liao, C.S. Chang, and W.C. Wei et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study Schizophr Res 126 2011 110 116
33. A. Hammerman, J. Dreiher, S.H. Klang, H. Munitz, A.D. Cohen, and M. Goldfracht Antipsychotics and diabetes: an age-related association Ann Pharmacother 42 2008 1316 1322
34. C.B. Jasik, and R.H. Lustig Adolescent obesity and puberty: the "perfect storm" Ann N Y Acad Sci 1135 2008 265 279 (Pubitemid 351862125)
35. R.S. McIntyre, and J.M. Jerrell Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents Arch Pediatr Adolesc Med 162 2008 929 935
36. W.L. Awa, E. Fach, and D. Krakow et al. Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the german/austrian DPV database Eur J Endocrinol 167 2012 245 254
37. S. Crystal, M. Olfson, C. Huang, H. Pincus, and T. Gerhard Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges Health Aff (Millwood) 28 2009 w770 w781
38. P. Knapp, A. Chait, E. Pappadopulos, S. Crystal, P.S. Jensen T-MAY Steering Group Treatment of maladaptive aggression in youth: CERT guidelines I. engagement, assessment, and management Pediatrics 129 2012 e1562 e1576
39. N. Scotto Rosato, C.U. Correll, and E. Pappadopulos et al. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management Pediatrics 129 2012 e1577 e1586
40. E. D'Adamo, and S. Caprio Type 2 diabetes in youth: epidemiology and pathophysiology Diabetes Care 34 Suppl 2 2011 S161 S165
41. O. Pinhas-Hamiel, and P. Zeitler Acute and chronic complications of type 2 diabetes mellitus in children and adolescents Lancet 369 2007 1823 1831 (Pubitemid 46783022)
42. P. Munk-Jorgensen, and S.D. Ostergaard Register-based studies of mental disorders Scand J Public Health 39 7 Suppl 2011 170 174
43. P. Manu, C.U. Correll, and M. Wampers et al. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs Eur Neuropsychopharmacol 23 2013 205 211